新诊断2型糖尿病患者血清前蛋白转化酶枯草溶菌素9水平的变化及其临床意义被引量：10

Serum PCSK9 level and its clinical value in patients with newly diagnosed type 2 diabetes

导出

摘要目的探讨前蛋白转化酶枯草溶菌素9(PCSK9)在新诊断T2DM患者及NGT人群中的差异及其与血糖、胰岛素及其他代谢指标的关系。方法选取新诊断T2DM患者200例和NGT者244名,ELISA检测血清PCSK9水平。结果 T2DM组血清PCSK9水平高于NGT组[(90.58±40.48)vs(63.09±33.83)ng/ml](P<0.01)。总人群血清PCSK9水平与年龄、SBP、BMI、WC、TC、TG、LDL-C、FPG、FIns、胰岛素抵抗指数(HOMA-IR)呈正相关,与HDL-C呈负相关(P<0.05);NGT组血清PCSK9水平与年龄、TC、LDL-C、FIns、HOMA-IR呈正相关(P<0.05);T2DM组血清PCSK9水平与TC、TG、LDL-C、FPG、FIns、HOMA-IR呈正相关(P<0.05)。多元逐步回归分析显示,LDL-C是PCSK9的影响因素,总人群及T2DM患者中,FPG是PCSK9的影响因素。结论 T2DM患者血清PCSK9水平高于NGT人群.PCSK9可能参与了糖尿病的发生发展。 Objective To investigatethe difference of proprotein convertase subtilisin/ kexin type 9（PCSK9） level between patients with newly diagnosed type 2 diabetes mellitus（T2DM） and people with normal glucose tolerance（NGT）,and evaluate the correlation between serum PCSK9 and glucose,insulin and other metabolic factors.Methods A total of 200 T2 DM patients and 244 NGT subjects were randomly enrolled in this study.Serum PCSK9 level was measured by EL1 SA.Results Serum PCSK9 level was higher in T2 DM group than in NGT group[（90.58 ± 40.48） vs（63.09 ±33.83）ng/ml]（P0.01）.Serum PCSK9 level was positively correlated with age,SBP,BMI,WC,TC,TG,LDL-C,FPG,Fins and HOMA-IR and negatively correlated with HDL-C（P〈0.05）.Serum PCSK9 level was positively correlated with age,TC,LDL-C,FIns and HOMATR in NGT group（P〈0.05） and positively correlated with TC,TG,LDL-C,FPG,FIns and HOMA-IR in T2 DM group（P〈0.05）.Multiple stepwise regression analysis showed that LDL-C was an influencing factor for PCSK9 and FPG was an influencing factor for PCSK9 in the whole study population and T2 DM group.Conclusion Serum PCSK9 level is higher in T2 DM patients than in NGT subjects.PCSK9 may play a role in the development of T2 DM.

作者郭雯欣冰杨涛李杰陈晓倩王亚梅上官海燕仲彬周红文

机构地区南京医科大学第一附属医院内分泌科南京市市级机关医院内分泌科

出处《中国糖尿病杂志》 CAS CSCD 北大核心 2016年第4期296-300,共5页 Chinese Journal of Diabetes

基金国家自然科学基金(81170747) 江苏省六大人才高峰(2008-18D)

关键词前蛋白转化酶枯草溶菌素9 糖尿病 2型低密度脂蛋白胆固醇 Proprotein convertase subtilisin/kexin type 9（PCSK9） Diabetes mellitus type 2 Low density lipoprotein-cholesterol（LDL-C）

分类号 R587.1 [医药卫生—内分泌]

引文网络
相关文献

参考文献12

1Ayyobi AF,Brunzell JD. Lipoprotein distribution in the meta- bolic syndrome,type 2 diabetes mellitus, and familial combined hyperlipidemia. Am J Cardiol, 2003,92 : 27J-33J.
2Cunningham D, Danley DE, Geoghegan KF, et al. Structural and biophysical studies of PCSK9 and its mutants linked to fa- milial hypercholesterolemia. Nat Struet Mol Biol, 2007, 141 413-419.
3Lakoski SG, Lagace TA, Cohen JC, et al. Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endoerinol Metab, 2009,94 : 2537-2543.
4Cui Q, Ju X, Yang T, et al. Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population. Atherosclerosis, 2010,213 : 632-636.
5Zaid A,Roubtsova A,Essalmani R,et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9) : hepatocyte-specific low-den-sity lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology, 2008,48 : 646-654.
6Mbikay M, Sirois F, Mayne J, et al. PCSK9-deficient mice ex- hibit impaired glucose tolerance and pancreatic islet abnormali- ties. Febs Lett, 2010,584 : 701-706.
7Coster P,Cariou B, Lambert G, et al. Hepatic PCSK9 expres- sion is regulated by nutritional status via insulin and sterol reg- ulatory element-binding protein lc. J Biol Chem, 2006, 281: 6211-6218.
8Kappelle PJ,Lambert G,Dullaart RP. Plasma proprotein con- vertase subtilisin-kexin type 9 does not change during 24h insu- lin infusion in healthy subjects and type 2 diabetic patients. Atherosclerosis, 2011,214 : 432-435.
9Li S, Guo YL,Xu RX, et al. Association of plasma PCSK9 lev- els with white blood cell count and its subsets in patients with stable coronary artery disease. Atherosclerosis, 2014, 234: 441-445.
10Langhi C, Le May C, Gmyr V, et al. PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretion. Bio- chem Biophys Res Commun, 2009,390 : 1288-1293.